Infusion Providers

Welcome! Here you can find resources for sites of care receiving and administering COVID-19 antibody infusions.

Interested in offering COVID-19 antibody therapeutics at your infusion center?

Important Update Regarding Bamlanivimab + Etesevimab Distribution

Important Notice: On June 25, 2021, the FDA is immediately pausing all distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supply of bamlanivimab at a facility for use under EUA 094) on a national basis until further notice.

Important Notice: On April 16, 2021, the FDA revoked emergency use authorization for bamlanivimab monotherapy due to the increased prevalence of SARS-CoV-2 variants that are expected to be resistant to bamlanivimab administered alone. This change comes at the request of the manufacturer, Eli Lilly, due to the availability of more efficacious monoclonal antibody therapies, and is not related to any adverse events or safety issues.  For more information, see the FDA’s Letter of Revocation, and Frequently Asked Questions on the Revocation of the Emergency Use Authorization for Bamlanivimab Administered Alone.

Virtual Event Opportunity with Medscape

Want to learn about neutralizing monoclonal antibodies in COVID-19 and infusion center operations? Click the button below to see any open slots available for a virtual event opportunity to get answers to your most pressing questions.

Locator Providers
Make sure patients and prescribers can find you.

Discover how your center can leverage the NICA COVID-19 Antibody Therapy Locator!

Drip Rate Tables Tile
Casirivimab + Imdevimab Drip Rate Tables

 Drip rates for administering COVID-19 antibody infusions by gravity. (Updated 6-9-21)

Casirivimab + Imdevimab Medication Safety Alert Tile
Casirivimab + Imdevimab Medication Safety Alert

Casirivimab and Imdevimab are supplied in multiple packaging configurations and have unique preparation requirements that may increase risk for medication errors.

Casirivimab + Imdevimab Flowsheet Tile
Casirivimab Imdevimab Flowsheet

Use this flowsheet to document infusion therapies and provide a detailed record to fax to the referring prescriber. The flowsheet also guides the clinician to adhere to administration and documentation requirements. (Updated 6-15-21)

Med Prep Area Checklist
Medication Preparation Area Checklist

Use this checklist to ensure your medication preparation area meets National Infusion Center Association standards. (Updated 1-21-2021)

Claim your Center
Claim Your Center

Make sure that your infusion center is listed and be sure to claim it and update your profile.

Discharge Instructions Tile (Providers)
Discharge Instructions

Be sure patients know what signs and symptoms to report after their infusion appointment. (Updated 5-20-21)

Med Stability and Storage
Medication Stability and Storage

Review these notes on medication stability and storage to ensure product and patient safety. (Updated 6-15-2021)

Minimum Standards tile
NICA Standards for In-Office Infusion

View NICA’s minimum standards for the administration of intravenous and injectable medication in an outpatient setting.

guidebook
Regeneron Casirivimab + Imdevimab Emergency Use Authorization (EUA) Guidebook

NICA collaborated with Regeneron to develop this playbook with in-depth information about Casirivimab + Imdevimab

Log in with your credentials

or    

Forgot your details?

Create Account